 | |
| Type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1 January 2004  |
| Headquarters | Pasadena, California, U.S. |
Key people | Christopher Anzalone, Ph.D., (president and CEO) |
| Revenue |  US$$829.4 million (2025)1 |
Number of employees | 609 |
| Website | arrowheadpharma |
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action.23 The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.2
History
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.45
In April 2016, the company announced a name change from Arrowhead Research Corporation to Arrowhead Pharmaceuticals, Inc.6
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead's ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.7
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.8
Products
The company has sixteen products in its pipeline, in various stages of development.2
| Product | Indication | Development phase | Notes |
|---|---|---|---|
| ARO-HBV2 | Hepatitis B | In clinic, phase 2 | Licensed with Janssen, Phase 2 |
| ARO-AAT2 | Alpha-1 antirypsin deficiency | In clinic, phase 3 | Orphan Drug designation, partnered with Takeda |
| ARO-APOC32 | Hypertriglyceridemia | Phase 2, 3 | Orphan Drug designation, Fast Track Designation, Phase 3 for FCS, Phase 2 for expanded populations |
| ARO-HIF22 | Renal cell carcinoma | Preclinical | Second generation being worked on presumably |
| ARO-ENaC2 | Cystic fibrosis | Preclinical | Second generation being worked on in preclinic |
| ARO-ANG32 | Dyslipidemia | In clinic, Phase 2 | Orphan Drug designation |
| Olpasiran/ AMG 8902 | Cardiovascular disease | In clinic, phase 3 | Partnered with Amgen |
| ARO-PNPLA3 | NASH | In clinic, Phase 1 | License returned to ARWR |
| ARO-HSD | NASH | In clinic, Phase 1 | Licensed to GSK |
| ARO-C3 | Complement Mediated Disease | In clinic, Phase 1 | |
| ARO-MUC5AC | Muco-obstructive | In clinic, Phase 1 | |
| ARO-RAGE | Inflammatory | In clinic, Phase 1 | |
| ARO-MMP7 | Idiopathic Pulmonary Fibrosis | In clinic, Phase 1 | |
| ARO-COV | COVID-19 | Preclinical | |
| ARO-DUX4 | FSHD | Preclinical | |
| HZN-457 | Gout | In clinic, Phase 1 | Partnered with Horizon |
References
References
- "Arrowhead Pharmaceuticals Reports Fiscal 2025 Year End Results". November 25, 2025.
- "arwr-10q_20170331.htm". www.sec.gov. Retrieved 2017-05-17.
- "8-K". www.sec.gov. Retrieved 2017-05-17.
- "Arrowhead buys Novartis' RNAi portfolio". Reuters. 2017-03-05. Retrieved 2017-05-17.
- Staff (1 April 2015). "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
- "Arrowhead Research Changes Name to Arrowhead Pharmaceuticals". www.businesswire.com. 2016-04-06. Retrieved 2020-04-06.
- "Amgen, Arrowhead team up on gene-therapies for heart disease". Reuters. 2017-09-29. Retrieved 2017-05-17.
- "Arrowhead Enters $3.7 Billion License and Collaboration". Marketwatch. 2018-10-04. Retrieved 2018-10-04.